fda stopping semaglutide Declares Shortage of Novo Nordisk's Wegovy, Ozempic Over FBI issues safety warning about

How It Works: DPP-4 inhibitors slow the enzymatic breakdown of GLP-1, effectively extending its half-life in circulation

Appetite suppression comes on more gradually

For practitioners treating GLP-1 agonist non-responders, understanding these biological adaptations proves essential, as they explain why willpower alone rarely suffices for sustainable results

This is where both sides retain medical and scientific experts, those experts prepare their reports and opinions, and the opposing side gets to challenge those opinions through a legal process called Daubert review

This efficacy suggests the drug could be suitable for patients with greater weight loss needs, including as an alternative to more invasive treatments like bariatric surgery